Daily EPS Performer Reports

Stocks detected early by our EPS revision screener — and how they performed.

2026-11-12
COHRWOLFRDWGRNTSITM

COHR Jumps 38.1% as EPS Revisions Fuel Tech Rally; WOLF, RDW, GRNT, SITM Surge

Coherent (COHR) led a broad rally in EPS-revision winners, surging 38.1% to $234.51 since November 5 as its forward EPS growth estimate rose to 54.9%. Wolfspeed (WOLF) gained 36.0% and Redwire (RDW) 35.7%, while Granite Ridge (GRNT) and SiTime (SITM) added 34.3% and 33.1%, respectively, as estimate hikes and positive catalysts drove outsized gains.

Read analysis →
2026-11-11
COHRWOLFGRNTSITMVCEL

COHR, WOLF, GRNT Lead Post-Earnings Surge: 38%, 36%, 34% Gains

Coherent (COHR) jumped 38.1% to $234.51, Wolfspeed (WOLF) rose 36.0% to $27.68, and Granite Ridge (GRNT) climbed 34.3% to $6.27, all after EPS estimate revisions following strong earnings. SiTime (SITM) and Vericel (VCEL) also gained 33.1% and 30.7%, respectively, as upbeat guidance and analyst upgrades drove the post-earnings rallies.

Read analysis →
2026-11-10
IVFGRNTWOLFOPTUVCEL

IVF Jumps 36.6% as EPS Revision Screener Catches Early Signal

INVO Fertility (IVF) led gains with a 36.6% jump to $2.50 after our screener flagged its 98.6% next-year EPS growth on November 2. Granite Ridge (GRNT) rose 29.1% to $6.03 on a strong earnings beat and upward EPS revision, while Wolfspeed (WOLF), Optimum (OPTU), and Vericel (VCEL) each gained over 28% as estimate revisions and catalysts drove price confirmation.

Read analysis →
2026-11-09
OPTUSITMIVFVCELWOLF

SITM Soars 28.8% as EPS Revisions Fuel Broad-Based Rally

Five stocks detected by our EPS revision screener delivered outsized gains, led by SiTime (SITM) up 28.8% to $457.05 after analysts raised its next-year EPS growth estimate from 32.4% to 43.3%. Optimum Communications (OPTU) and Vericel (VCEL) each gained over 28% as earnings beats and restructuring catalysts confirmed the revisions, while INVO Fertility (IVF) and Wolfspeed (WOLF) rounded out the top performers with gains exceeding 28% apiece.

Read analysis →
2026-11-07
TREEDFHVCELIVFTBBB

TREE Jumps 26.5% as EPS Revision and Buyback Fuel Post-Earnings Rally

LendingTree (TREE) surged 26.5% after a $98.8M goodwill impairment masked a revenue beat and first buyback since 2022, while Dream Finders Homes (DFH) gained 22.8% on a 108.6% next-year EPS growth estimate and Vericel (VCEL) rose 20.1% after a 1,250% earnings surprise and raised guidance. The screeners caught EPS revisions ahead of these moves, with TREE and VCEL posting the strongest post-detection gains among the group.

Read analysis →
2026-11-06
NMRAREPLDFHRYTMJBLU

NMRA, REPL Lead Healthcare Surge: EPS Revisions Fuel 20%+ Gains

Neumora Therapeutics (NMRA) jumped 28.2% and Replimune Group (REPL) rose 24.3% after their forward EPS estimates were revised upward on October 29, 2026. Dream Finders Homes (DFH), Rhythm Pharmaceuticals (RYTM), and JetBlue Airways (JBLU) also posted gains of over 20% as the market validated the screener's early detection of earnings estimate revisions.

Read analysis →
2026-11-05
NMRAREPLUBURCSGP

U Leads 23.5% EPS Revision Rally; REPL, BUR, CSGP Also Surge

Unity Software (U) jumped 23.5% to $48.80 after its Q3 beat and first GAAP profit, while Replimune (REPL) rose 24.7% on a narrower loss and TUDRIQEV launch progress. Burford Capital (BUR) gained 17.2% on a Q3 beat and debt reduction, and CoStar (CSGP) added 16.4% after upgrading its multifamily forecast. Neumora (NMRA) climbed 25.6% on a modest EPS revision with no news.

Read analysis →
2026-11-04
NMRAREPLBURRYTMCSGP

NMRA Jumps 46% as EPS Revisions Fuel Biotech Rally; REPL, BUR Follow

Neumora Therapeutics (NMRA) led gainers with a 46.1% surge since its October 29 EPS estimate revision, while Replimune (REPL) rose 28.8% after beating Q2 estimates and launching its melanoma therapy TUDRIQEV. Burford Capital (BUR) climbed 23.1% following a strong Q3 beat and debt reduction, and Rhythm Pharmaceuticals (RYTM) gained 18.9% on accelerating IMCIVREE sales and expanded NICE guidance.

Read analysis →
2026-11-03
NMRACOSMREPLXLOVRT

NMRA Jumps 46% as Healthcare Small Caps Lead EPS Revision Rally

Neumora Therapeutics (NMRA) surged 46.1% to $0.57 after its next-year EPS growth estimate was revised up 1.1 percentage points on October 29, leading a broad rally in EPS-revision small caps. Cosmos Health (COSM) gained 30.4% following a 14.8-point upward revision, while Replimune (REPL) rose 28.6% after beating Q2 estimates and launching its melanoma therapy TUDRIQEV. Vertiv (VRT) added 18.1% on a blowout quarter and fourth guidance raise.

Read analysis →
2026-11-02
COSMNMRAGMABREPLDNUT

Healthcare Micro-Caps Lead: COSM +34.8%, NMRA +28.2%, GMAB +25.4% on EPS Revisions

Cosmos Health (COSM) surged 34.8% to $0.31 after its next-year EPS growth estimate was revised up 14.8 percentage points to 146.7% on October 26. Neumora Therapeutics (NMRA) gained 28.2% to $0.50 following a 1.1pp upward revision to 31.1%, and Genmab (GMAB) jumped 25.4% to $54.92 after positive Phase 3 cancer trial results and a J.P. Morgan upgrade reinforced its 46.3% EPS growth outlook.

Read analysis →
2026-10-31
COSMGMABSLNHXTIAINSM

COSM Jumps 34.8% as EPS Revision Screener Flags Strongest Movers

Cosmos Health (COSM) led gainers with a 34.8% rally to $0.31 after its next-year EPS growth estimate was revised up 14.8 percentage points to 146.7% on October 26. Genmab (GMAB) rose 30.3% to $57.06 following positive Phase 3 cancer trial results and a J.P. Morgan upgrade, while Soluna (SLNH) gained 26.4% to $0.67 on its Applied Digital joint venture. XTI Aerospace (XTIA) and Insmed (INSM) added 23.5% and 20.6%, respectively, as earnings-estimate revisions preceded price confirmation across the group.

Read analysis →
2026-10-30
COSMGMABSLNHXTIAINSM

COSM +34.8%, GMAB +30.3% Lead Post-EPS Revision Surges

Cosmos Health (COSM) jumped 34.8% to $0.31 after its next-year EPS growth estimate was revised from 131.8% to 146.7% on October 26, while Genmab (GMAB) rose 30.3% to $57.06 following a 46.3% EPS growth estimate and positive Phase 3 head and neck cancer trial data that reduced death risk by 50%. Soluna Holdings (SLNH) gained 26.4%, XTI Aerospace (XTIA) added 23.5%, and Insmed (INSM) climbed 20.6% as the EPS revision screener flagged upward estimate momentum across healthcare, financial, and industrial small caps.

Read analysis →
2026-10-29
EAFSLNHXTIAGMABCOSM

EAF Soars 73% on Pricing Inflection: Inside Today's Top EPS Revisions

GrafTech (EAF) surged 73.4% to $12.05 after its Q3 earnings beat and management guided to higher realized pricing in Q4 and 2027. Soluna (SLNH) and XTI Aerospace (XTIA) also posted strong gains of 32.1% and 30.6% respectively, while Genmab (GMAB) and Cosmos Health (COSM) rounded out the top performers with 29.0% and 21.7% advances, all driven by positive EPS estimate revisions.

Read analysis →
2026-10-28
EAFGMABKIDSSLNHXTIA

EAF Soars 75% on Pricing Inflection; GMAB, KIDS, SLNH Lead EPS-Revision Rally

GrafTech International (EAF) surged 75.2% to $12.18 after guiding to a Q4 pricing increase and closing its highest-cost plant, following an EPS growth estimate of 35.0% for next year. Genmab (GMAB) rose 48.8% to $57.29 on a J.P. Morgan upgrade and positive Phase 3 cancer trial data, while OrthoPediatrics (KIDS) gained 39.8% to $30.80 after its third consecutive revenue guidance raise. Soluna Holdings (SLNH) and XTI Aerospace (XTIA) added 35.9% and 28.2%, respectively, on HPC joint-venture and drone revenue news.

Read analysis →
2026-10-27
EAFHPPSLNHGMABESTA

EAF Jumps 70.2%, HPP 23.2%, SLNH 22.6% as EPS Revisions Pay Off

GrafTech International (EAF) surged 70.2% from $6.95 to $11.83 after its upward EPS revision and a Q3 beat with a pricing inflection call. Hudson Pacific Properties (HPP) gained 23.2% to $11.11 on a 30.5% next-year EPS growth estimate, while Soluna Holdings (SLNH) rose 22.6% to $0.65 on a 33.3% growth estimate and a new Applied Digital joint venture.

Read analysis →
2026-10-26
EAFHPPGRNTGMABDAKT

EAF Leads 5 Stock Surge on EPS Revisions: EAF +53%, HPP +26%

GrafTech International (EAF) surged 53.2% to $10.65 after its Q3 beat and guidance for higher Q4 pricing, while Hudson Pacific Properties (HPP) gained 26.1% on a 30.5% next-year EPS growth estimate. Granite Ridge Resources (GRNT) rose 16.1% after its EPS growth estimate was revised up 15.8 percentage points, and Genmab (GMAB) added 16.1% on positive cancer trial data.

Read analysis →
2026-10-23
BRCBEAFHPPALMRHUBS

BRCB Jumps 35.9%, EAF 22.4% on EPS Revisions: Top Gainers

Black Rock Coffee Bar (BRCB) led our EPS-revision screener with a 35.9% gain to $9.81 after its next-year EPS growth estimate rose to 30.0% on October 14, while GrafTech (EAF) added 22.4% to $8.51 after guiding to a Q4 pricing inflection. Hudson Pacific (HPP) rose 21.9%, Alamar Biosciences (ALMR) 21.0%, and HubSpot (HUBS) 19.7%, as upward estimate revisions preceded strong price confirmation across Consumer Cyclical, Industrials, Real Estate, Healthcare, and Technology.

Read analysis →
2026-10-22
BRCBAPPNREAXHUBSHPP

BRCB Soars 33.7% on EPS Revision; APPN, REAX, HUBS, HPP Also Surge

Black Rock Coffee Bar (BRCB) jumped 33.7% since its EPS revision was detected on October 14, leading a group of stocks with upward estimate revisions. Appian (APPN) gained 32.1%, Real REMAX Group (REAX) 20.0%, HubSpot (HUBS) 18.1%, and Hudson Pacific Properties (HPP) 17.3%, as the market validated the screener's early detection of improving earnings prospects.

Read analysis →
2026-10-21
APPNALMRBRCBREAXAGIO

APPN Jumps 25.9% on EPS Revision; ALMR, BRCB, REAX, AGIO Also Surge

Appian (APPN) led gains, jumping 25.9% to $48.73 after its next-year EPS growth estimate was revised to 31.3% on October 13, supported by Citi's bullish AI-demand call. Alamar Biosciences (ALMR) rose 24.0% following a 3.8pp upward EPS revision to 49.1%, while Black Rock Coffee Bar (BRCB) gained 19.9% after its estimate ticked up to 30.0%.

Read analysis →
2026-10-20
REAXBRCBAPPNAGIOCSGP

REAX Jumps 26% as EPS Growth Estimate Nearly Doubles

Real REMAX Group (REAX) surged 26.0% to $17.14 after its forward EPS growth estimate was revised from 195.2% to 294.2% on October 14. Black Rock Coffee Bar (BRCB) gained 19.4% following a modest 1.3pp upward revision to 30.0%, while Appian (APPN) rose 15.0% on analyst optimism and an upcoming earnings date. The screen caught these revisions early, and price action has since confirmed the improving fundamentals.

Read analysis →
2026-10-19
BRCBREAXBRBRTVAPPN

BRCB, REAX, BRBR Lead: 5 Stocks Surge on EPS Revision (10.4%–17.3%)

Five stocks detected by our EPS revision screener between October 13 and 14 delivered outsized gains by October 19, led by Black Rock Coffee Bar (BRCB) at +17.3% and Real REMAX Group (REAX) at +13.3%. The strongest estimate jump came from REAX, whose next-year EPS growth forecast nearly doubled to 294.2% (+99.0 percentage points), while Appian (APPN) benefited from a Citi bullish call on AI process automation demand.

Read analysis →
2026-10-16
VRATVCSGPBRBRALHC

VRA Jumps 13.8% as EPS Growth Estimate Revised to 150%

Vera Bradley (VRA) led our EPS revision screener with a 13.8% gain to $5.85 after its next-year EPS growth estimate was revised from 86.4% to 150%. Grupo Televisa (TV) rose 11.8% to $2.47, while CoStar Group (CSGP) and BellRing Brands (BRBR) each gained over 10% as upward estimate revisions drove broad-to-sector-specific momentum.

Read analysis →
2026-10-15
MRNAVRAWQEYRGENAGBK

MRNA Jumps 20.1% on EPS Revision and Goldman Upgrade; VRA, WQEY, RGEN Surge

Moderna (MRNA) leads today's EPS revision screen with a 20.1% gain to $236.50 since detection on October 8, driven by a 42.9% next-year EPS growth estimate and a Goldman Sachs price target hike ahead of key melanoma data. Vera Bradley (VRA) rose 16.5% after its next-year EPS growth estimate was revised from 86.4% to 150.0%, while WISeQey (WQEY) and Repligen (RGEN) gained 14.2% and 12.4% respectively on upward estimate revisions.

Read analysis →
2026-10-14
MRNANVAXAGBKWQEYVRA

MRNA Jumps 14.9%, NVAX Up 12.7% as Healthcare Stocks Ride EPS Revisions

Moderna (MRNA) surged 14.9% to $226.30 after its forward EPS growth estimate was revised to 42.9%, while Novavax (NVAX) rose 12.7% to $12.64 on a 20-percentage-point EPS revision for next year. Other notable gainers included AGBK (+10.4%), WQEY (+10.2%), and VRA (+9.5%), driven by upward earnings estimate revisions across sectors.

Read analysis →
2026-10-13
SEZLNVAXAGBKVRASNAP

SEZL Jumps 15% as EPS Growth Estimate Hits 27.3%

Sezzle (SEZL) led today's EPS-revision gainers with a 15.2% rally to $130.05 after our screener detected a 27.3% next-year EPS growth estimate on Oct 6, reinforced by its Nov 4 Q3 earnings date announcement. Novavax (NVAX) rose 14.3% on a +20.0pp upward revision to 97.3% growth, AGBK added 13.4% on a 44.5% estimate, while Vera Bradley (VRA) and Snap (SNAP) gained 12.4% and 11.7% respectively on upward EPS revisions.

Read analysis →
2026-10-12
SEZLNVAXRZLTSNAPPRCT

Sezzle Leads EPS Revision Screen with 15.6% Jump; NVAX, RZLT Follow

Sezzle (SEZL) jumped 15.6% to $130.48 after its next-year EPS growth estimate was revised to 27.3% on October 6, reinforced by TD Cowen's bullish note highlighting its 77% YTD gain and upcoming Q3 earnings. Novavax (NVAX) rose 12.8% to $12.66 following a 20-point upward revision to its next-year EPS growth estimate, while Rezolute (RZLT) gained 12.7% to $4.87 after the FDA recommended a pre-BLA meeting for Ersodetug despite a Phase 3 miss. Snap (SNAP) and PROCEPT BioRobotics (PRCT) also posted double-digit and near-double-digit gains, respectively, as estimate revisions and catalysts aligned.

Read analysis →
2026-10-10
SEZLNVAXRZLTAIDXFSM

Small-Cap EPS Revision Stocks Surge: SEZL +14%, NVAX +13.6% Lead

Sezzle (SEZL) led today's EPS revision screen with a 14.0% gain to $128.64 after analysts raised its next-year EPS growth estimate to 27.3% and the company scheduled Q3 results, while Novavax (NVAX) jumped 13.6% to $12.75 on a 20.0pp upward revision to its 2027 EPS growth outlook. Rezolute (RZLT) added 12.7% to $4.87 after the FDA recommended a pre-BLA meeting for Ersodetug, and Fortuna Mining (FSM) and 20/20 Biolabs (AIDX) gained 7.9% and 8.6% respectively as the market validated early estimate revisions across healthcare and materials.

Read analysis →
2026-10-09
PENGCLFSEZLRZLTJBS

PENG Jumps 24.3% on Raised FY27 Outlook; CLF, SEZL Also Surge

Penguin Solutions (PENG) gained 24.3% to $76.28 after analysts hiked price targets to as high as $100 on a Q4 beat and a raised fiscal 2027 EPS outlook of $4.45. Cleveland-Cliffs (CLF) jumped 14.7% to $12.98 after Wells Fargo upgraded the stock to Overweight with a $14 target. Sezzle (SEZL) rose 14.0% to $128.64, and Rezolute (RZLT) added 12.7% to $4.87 on an FDA pre-BLA meeting recommendation, while JBS gained 11.2% to $12.98.

Read analysis →
2026-10-08
PENGSOCAFRMJBSWLTH

PENG Soars 16.6% on AI Memory Beat; SOC, AFRM, JBS, WLTH Also Rally

Penguin Solutions (PENG) jumped 16.6% since October 2 after analysts raised forward EPS growth estimates to 29.2%, driven by a record fiscal Q4 with revenue up 68% to $567 million and 2027 guidance well above consensus. Sable Offshore (SOC) gained 10.0% on a 5.1pp EPS revision to 152.0%, while Affirm (AFRM) rose 9.5% ahead of Q3 earnings, and JBS and Wealthfront added 9.2% and 8.6% respectively on estimate upgrades.

Read analysis →
2026-10-07
PENGCOHRPSGOTUAVGO

PENG Soars 18.3% on AI Factory Blowout; COHR, AVGO Lead Tech Surge

Penguin Solutions (PENG) jumped 18.3% since its October 2 EPS revision detection, closing at $72.61 after a record fiscal Q4 that featured 68% revenue growth, non-GAAP EPS of $1.00 (beating 77-cent consensus), and a massive raised fiscal 2027 outlook. Coherent (COHR) gained 16.2% to $334.56 as AI infrastructure spending optimism lifted the entire semiconductor ecosystem, while Broadcom (AVGO) rose 9.6% to $376.51 on news it assembled $60 billion in debt financing to fund Anthropic AI chip infrastructure. The five-day rally across PENG, COHR, PS, GOTU, and AVGO reflects a market intensely rewarding companies that can prove AI-driven earnings acceleration.

Read analysis →